Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachna T Shroff

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic AdenocarcinomaBach Ardalan, Aaron Ciner, Yasmine Baca, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Cancers|December 22, 2020
Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal AdenocarcinomaLoryn Holokai, Jayati Chakrabarti, Joanne Lundy, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 4, 2023
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with CholangiocarcinomaRikita I Hatia, Madhulika Eluri, Ernest T Hawk, et al.
The Oncologist|March 13, 2025
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence databaseAbrahm Levi, Edik Blais, John Davelaar, et al.
Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.
JCO Precision Oncology|February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical PhenotypeApurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
JCO Precision Oncology|February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase InhibitorsMorten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic AdenocarcinomaBach Ardalan, Aaron Ciner, Yasmine Baca, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
Cancers|December 22, 2020
Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal AdenocarcinomaLoryn Holokai, Jayati Chakrabarti, Joanne Lundy, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 4, 2023
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with CholangiocarcinomaRikita I Hatia, Madhulika Eluri, Ernest T Hawk, et al.
The Oncologist|March 13, 2025
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence databaseAbrahm Levi, Edik Blais, John Davelaar, et al.
Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.
JCO Precision Oncology|February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical PhenotypeApurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
JCO Precision Oncology|February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase InhibitorsMorten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Pageof 8